SecBot SecBot
424B4 ·Filed Feb 27, 2026

GENB

Generate Biomedicines, Inc.
BEARISH
Impact 7/10
Horizonmonths Processed8mo ago SEC0001193125-26-083190
Prospectus supplement
Actionable Insight ▼ Bearish

The IPO provides crucial capital for a cash-burning biotech, but the going concern warning and high-risk clinical-stage profile make this a speculative investment. Traders should monitor upcoming clinical trial data for GB-0895 and the company's cash burn rate as key catalysts.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.17
T+0 close · Feb 27, 2026 · via day close
Latest settled
+9.61%
T+60 · $13.34
Vs SPY
+0.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $12.17entry
  2. T+1 · 9mo ago −1.97%α −1.06% · $11.93
  3. T+5 · 8mo ago 0.00%α +1.21% · $12.17
  4. T+20 · 8mo ago −5.42%α +2.52% · $11.51
  5. T+60 · 6mo ago +9.61%α +0.29% · $13.34

Executive Summary

Generate Biomedicines is pricing its IPO of 25 million shares at $16.00 per share, raising $400 million in gross proceeds. The company, a clinical-stage biotech using AI to design protein therapeutics, plans to use the funds primarily to advance its lead candidate GB-0895 through Phase 3 trials for severe asthma and to fund platform development. Despite promising early data, the company faces significant risks, including substantial doubt about its ability to continue as a going concern due to recurring losses and limited cash runway.

Key Facts

  • IPO of 25 million shares priced at $16.00 per share, raising $400 million in gross proceeds ($374 million net before expenses).
  • Company has no approved products and has incurred significant losses, with a net loss of $223 million in 2025 and an accumulated deficit of $676.3 million.
  • Management and auditors have concluded there is substantial doubt about the company's ability to continue as a going concern.
  • Proceeds will be used to advance lead candidate GB-0895 through Phase 3 trials, complete a Phase 1b trial for COPD, and fund platform innovation.
  • The company is dependent on the success of its product candidates, including GB-0895, GB-4362, and GB-5267, and its ongoing and anticipated trials may not be successful.

Financial Impact

The offering will raise $374 million in net proceeds, which the company believes will fund operations into the first half of 2028. The company had $221.5 million in cash as of December 31, 2025.

cashdilutionrevenuedebt

Risk Factors

  • Substantial doubt about the company's ability to continue as a going concern.
  • High risk associated with clinical-stage biotech, including the possibility that product candidates may not be successful in trials.
  • Heavy reliance on the success of the lead product candidate, GB-0895.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B4 Filing (Primary)0001193125-26-083190
Document: 0001193125-26-083190-index-headers.html0001193125-26-083190
Document: 0001193125-26-083190-index.html0001193125-26-083190
Document: 0001193125-26-083190.txt0001193125-26-083190

Track record

11 reports on GENB

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +14.28% at T+20 after the Oct 1, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 5/10 Entry $12.57 Now $10.49 +16.55% settles Dec 11
  2. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $12.57 Now $10.49 −16.55% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $13.85 Now $10.49 −24.26% settles Dec 2
  4. Oct 29, 202618d ago 144 Neutral 2/10 Entry $14.46 Now $10.49 −27.46% settles Nov 30
  5. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $12.52 to $13.49 Now $10.49 −16.21% ▲ +7.75% +9.02% vs SPY
  6. Oct 1, 20266w ago Press Release Bullish 5/10 Entry $13.80 to $15.77 Now $10.49 −23.99% ▲ +14.28% +13.57% vs SPY
  7. May 7, 202627w ago 8-K Bearish 6/10 Entry $13.59 to $12.91 Now $10.49 +22.81% ▲ +5.00% +8.14% vs SPY
  8. Mar 2, 202637w ago Insider Cluster Bullish 7/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
  9. Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
  10. Feb 27, 202637w ago 424B4 Bearish 7/10 Viewing Entry $12.17 to $11.51 Now $10.49 +13.80% ▲ +5.42% −2.52% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 7h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 27, 2026